Attached files
file | filename |
---|---|
EX-32.2 - EXHIBIT 32.2 - TG THERAPEUTICS, INC. | tgtx_ex322.htm |
EX-32.1 - EXHIBIT 32.1 - TG THERAPEUTICS, INC. | tgtx_ex321.htm |
EX-31.2 - EXHIBIT 31.2 - TG THERAPEUTICS, INC. | tgtx_ex312.htm |
EX-10.19 - EXHIBIT 10.19 - TG THERAPEUTICS, INC. | v032117_EX1019.htm |
EX-10.18 - EXHIBIT 10.18 - TG THERAPEUTICS, INC. | v032117_EX1018.htm |
10-K/A - 10-K/A - TG THERAPEUTICS, INC. | v032117_10KA.htm |
Exhibit 31.1
CERTIFICATION OF PERIODIC
REPORT
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002
I, Michael S.
Weiss, certify that:
|
1.
|
I have reviewed this annual report on Form 10-K
of TG Therapeutics, Inc.;
|
|
2.
|
Based on my knowledge, this report does not
contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not
misleading with respect to the period covered by this
report;
|
|
3.
|
Based on my knowledge, the consolidated
financial statements, and other financial information included in
this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;
|
|
4.
|
The registrant’s other certifying officer
and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
|
|
a)
|
Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being
prepared;
|
|
b)
|
Designed such internal control over financial
reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting
principles;
|
|
c)
|
Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
|
|
d)
|
Disclosed in this report any change in the
registrant’s internal control over financial reporting that
occurred during the registrant’s most recent fiscal quarter
(the registrant’s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal
control over financial reporting; and
|
|
5.
|
The registrant’s other certifying officer
and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the
registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the
equivalent functions):
|
|
a)
|
All significant deficiencies and material
weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect
the registrant’s ability to record, process, summarize and
report financial information; and
|
|
b)
|
Any fraud, whether or not material, that
involves management or other employees who have a significant role
in the registrant’s internal control over financial
reporting.
|
Date: March 21,
2017
|
|
/s/ Michael S.
Weiss
|
|
Michael S.
Weiss
Executive Chairman, Chief Executive Officer and President Principal Executive Officer |